Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

KLOW

CombinationPreclinicalPubMed records: 900count from PubMed, not curated
Ask Eagle AI about this compound

Overview

Written by EagleThis description was written by Eagle in each of the three languages. It is not imported text and carries no translation warning. What it says comes from the compound’s own composition, its pharmacological class and what the library records — no efficacy claim, and no Eagle recommendation of use.

A record of a combination of three peptides — KPV, GHK-Cu and BPC-157 — presented as a single preparation rather than as a new molecule. Each component has its own page in this library, with chemical, safety and reference data shown when available.

KLOW is catalogued under Combination. 0 Eagle articles in this library reference this compound.

Category
Combination
Research stage
Preclinical — Pré-clínico (os 3 componentes extensivamente estudados isoladamente) Original in PT-BR
PubMed records
900 (count from PubMed, not curated)
Eagle articles on this compound
0 Eagle articles

Mechanism

KPV (anti-inflamatório via inibição de NF-κB) + GHK-Cu (remodelamento de colágeno) + BPC-157 (angiogênese/reparo) — indicado para pele sensível, rosácea e condições inflamatórias cutâneas Original in PT-BR

O KPV é o tripeptídeo C-terminal do alfa-MSH, com ação anti-inflamatória potente via inibição direta da translocação nuclear do NF-κB, sem suprimir a imunidade adaptativa — reduz citocinas pró-inflamatórias (TNF-α, IL-1β, IL-6) no tecido. O GHK-Cu remodela a matriz extracelular e estimula síntese de colágeno/elastina, além de ter ação antioxidante via upregulation da superóxido dismutase. O BPC-157 complementa com angiogênese via VEGFR2 e modulação do óxido nítrico, acelerando o suprimento sanguíneo a áreas inflamadas ou lesionadas. A combinação ataca simultaneamente inflamação, regeneração de matriz e vascularização. Original in PT-BR

Chemical information

CAS
N/A (blend proprietário) Original in PT-BR
Molecular formula
Ver componentes individuais Original in PT-BR
Molecular weight
Não se aplica à mistura — ver componentes individuais Original in PT-BR
Sequence
Ver componentes individuais Original in PT-BR
Amino acids
Ver componentes individuais Original in PT-BR
Solubility
Solúvel em água bacteriostática Original in PT-BR
Stability
Reconstituído: 28 dias refrigerado; liofilizado: 24 meses à temperatura ambiente Original in PT-BR
Half-life
KPV: ~2h / GHK-Cu: ~1h / BPC-157: ~4h Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
Redução de inflamação em 1-2 semanas; regeneração cutânea em 4-6 semanas Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

82/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • KPV inibe NF-κB e reduz inflamação sem imunossupressão Original in PT-BR

    PMID: 10940882Year: 2006Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • GHK-Cu remodela matriz extracelular e aumenta colágeno/elastina Original in PT-BR

    PMID: 24508109Year: 2015Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • BPC-157 promove angiogênese via VEGFR2 e via FAK-paxilina Original in PT-BR

    PMID: 36416831Year: 2022Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Vermelhidão no local de injeção
  • Leve náusea (raro)
  • Sensação de calor local (GHK-Cu)

Contraindications

  • Câncer ativo (BPC-157 promove angiogênese)
  • Gravidez
  • Doença de Wilson ou distúrbios do metabolismo do cobre

Warnings

  • Monitorar sinais de crescimento tecidual anormal
  • Ciclar uso: 4-6 semanas on / 2 semanas off recomendado

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for KLOW.

Lab tests named in the source

  • Cobre sérico (uso prolongado de GHK-Cu)
  • PCR
  • Hemograma completo

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose diária
1,5-3 mg do blend Original in PT-BR
Frequência
1x/dia SC Original in PT-BR
Volume/dose
9-19 UI na seringa U100 (frasco 80mg + 5mL BAC = 16 mg/mL; 1,5-3 mg do blend ≈ 9,4-18,8 UI, arredondadas) Original in PT-BR
Duração ciclo
4-6 semanas Original in PT-BR

Vial sizes: 80mg (blend KLOW) — Peptide Calculator

Interactions

These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

  • GLOWCombination

    Não recomendado combinar — sobreposição de componentes (GHK-Cu e BPC-157 em ambos) Original in PT-BR

Compatible

Caution

Related

No Eagle article in this library references this compound yet.

← Back to knowledge area